129
The term ‘phenomics’ is coined to describe, in anticipation, the new fi eld that is
likely to form from the behavioral and other phenotypic analyses designed to obtain
a large amount of information on the varying effects of genetic mutations. This will
integrate multidisciplinary research, with the goal of understanding the complex
phenotypic consequences of genetic mutations at the level of the organism. Hardware
and software engineers, as well as behavioral (and other) neuroscientists will co-
develop test paradigms and equipment that will enable investigators to cope with the
demands set by the increasing number of mutants generated by such techniques as
transgenics or chemical mutagenesis. Phenomics will be a crucial approach in aca-
demic, as well as industrial, research and could lead to a signifi cant paradigm shift
both in the genetic analysis of brain function and in drug development.
The Phenome platform system of DNAPrint Inc will help identify an individual
predisposed to develop cancer before the onset of illness so that lifestyles can be
altered and/or preventative measures taken. It will be used to identify individuals
who are incompatible with certain drug treatments before the drugs are prescribed
and damage is done. It will be used to tease out important genetic determinants
associated with complex genetic diseases, so that drugs can be developed to target
these genes.
Table 4.8 Examples of genotyping and phenotyping in some diseases
Disease Clinical features
Precipitating
factors Phenotyping Genotyping
α1-antitrypsin
defi ciency
(AAT)
Early onset of
emphysema
and liver
failure
Smoking Plasma
α1-antitrypsin
concentration
30 AAT gene
mutations on
chromosome
14q31-32.3
Congenital
adrenal
hyperplasia
An autosomal
recessive
disorder with
several clinical
manifestations
Serum
17-hydroxy-
progesterone
levels
50 mutations of
21-hydroxylase
(CYP21) gene
on
chromosome
6p21.3 near
HLA-B locus
Cystic fi brosis Build-up of thick,
sticky mucus
in the airways
Liver disease and
malabsorption
reduces drug
availability
Sweat chloride
concentration
1,000 mutations
of CFTR gene
on
chromosome
7q31
Glucose-6-
phosphate
dehydrogenase
defi ciency
Growth
retardation,
hypoglycemia,
intravascular
hemolysis
Drugs:
antimalarials,
sulfonamides,
quinidine
Absence of
ultraviolet-
induced
fl uorescence
of
erythrocytes
Point mutations of
G6PD gene on
chromosome
Xq28
© Jain PharmaBiotech
Role of Pharmacogenetics in Pharmaceutical Industry